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A key approach in understanding how breast cancer
can occur is to determine the regulatory pathways at
play in the normal breast and to identify precisely the
normal developmental mechanisms subverted during
early breast cancer progression. Using normal human
breast tissue samples, Pardo and colleagues have
identified the gene targets and pathways displaying
fluctuating expression as a consequence of the
menstrual cycle. Detailed characterization of how the
human breast functions in its normal state, and how
this may be perturbed at its earliest point, will provide
a critical step toward the prevention of breast cancer.our current understanding of normal breast develop-Although breast cancer mortality rates have decreased
over recent years, incidence rates continue to increase.
There is broad acceptance that strategies focused on
disease prevention and identification of early malignant
change are most likely to contribute to real improve-
ments in breast cancer incidence. Understanding the
molecular landscape of the normal breast is a critical
step in developing such approaches. The article by Pardo
and colleagues [1] in the previous issue of Breast Cancer
Research contributes an exciting new resource that
addresses that goal.
Recent advances in whole-genome sequencing and
expression profiling have profoundly expanded our under-
standing of the malignant landscape [2,3], yet the com-
bined complement of genes expressed in cancer tissue at
the time of sampling fail to provide insight into biological
pathways involved in carcinogenesis. Defining the molecu-
lar events in the normal breast which contribute to the
formation of a breast tumor remains elusive, and the* Correspondence: heidi.hilton@sydney.edu.au
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2014prevention of breast cancer at its earliest stages continues
to be a holy grail in breast cancer management. Although
it has long been known that the hormonal milieu of the
breast influences normal tissue development [4] and that
exposure to exogenous hormone analogues in hormone
replacement therapy and oral contraceptives contributes
adversely to breast cancer risk [5,6], there is a paucity of
information on the molecular events underlying this influ-
ence in humans.
Understanding regulatory pathways at play in the nor-
mal breast and the precise identification of normal de-
velopmental mechanisms subverted during early breast
cancer progression are key steps toward prevention.
Owing partly to a lack of appropriate models, much of
ment derives from studies in animals and, remarkably,
details of how the normal human breast functions re-
main largely unknown. A landmark study by Longacre
and Bartow [7] in 1986 described the morphological
changes occurring in the normal breast during the men-
strual cycle. In that study, histologic features, including
mitoses, were described in a cohort of 75 premenopausal
normal breast autopsy specimens, matched exactly to
menstrual cycle phase by endometrial dating. The inves-
tigators discovered a striking correlation between men-
strual cycle phase and proliferation, with the number of
mitoses peaking with higher levels of circulating proges-
terone. This study was the first to directly implicate pro-
gesterone in driving cyclical development in the normal
breast and is consistent with key epidemiological find-
ings reported by Pike and colleagues [8], who postulated
that this increased mitotic activity during the luteal
phase is associated with a transient increase in breast
cancer risk.
The article by Pardo and colleagues [1] takes the ap-
proach of Longacre and Bartow to the molecular level,
resulting in an interesting series of discoveries, which
both confirm and extend the findings of the 1986 study.
A major strength of this new study is the utilization ofentral Ltd. This is an Open Access article distributed under the terms of the
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donors to the Susan G. Komen for the Cure Tissue Bank
at the IU Simon Cancer Center (KTB). By laser capture
microdissecting the ductal epithelium of these samples
followed by next-generation RNA sequencing, they iden-
tified the gene targets and pathways displaying fluctuat-
ing expression during the menstrual cycle in the normal
human breast.
They demonstrated that 255 genes were differentially
expressed between the follicular and luteal phases of the
menstrual cycle. The vast majority of these (87%) dis-
played higher expression during the luteal phase, when
serum concentrations of progesterone are higher. Signifi-
cantly upregulated targets during the luteal phase were
enriched for functions relating to cell cycle, cellular
organization and repair, and DNA replication, recombin-
ation, and repair. These findings confirm the prolifera-
tive role of progesterone demonstrated in models of
normal human breast [9] and in the murine mammary
gland [10]. Data derived from mouse models have shown
that progesterone regulates the mammary stem cell
compartment during pregnancy and the reproductive
cycle [11,12], a mechanism suggested to account for the
increased window of susceptibility to transformation at
these times.
Interestingly, many of the proliferative targets that
Pardo and colleagues identified to be upregulated during
the luteal phase are also associated with overexpression
in breast cancer. Could dysregulation of these particular
gene sets similarly represent a transient period of in-
creased susceptibility to tumorigenesis during the luteal
phase in the human breast? As this study shows that the
genetic signature of the breast epithelium of women tak-
ing hormonal contraception resembles that of a continu-
ous luteal phase, the altered regulation of these gene sets
could also provide a potential mechanism to account for
the increased breast cancer risk associated with
progestin-containing oral contraception [6]. Moreover,
progesterone regulation of these gene sets may underlie
its hypothesized role as a promoter of malignant lesions
in the breast [13-15].
As healthy women are frequently exposed to changes
in their hormonal milieu, it will now be critical to deter-
mine whether this is indeed the case. Identification of
such specific gene sets and pathways which contribute
to increased breast tumor susceptibility could then pro-
vide novel indicators of breast cancer risk, prognosis, or
treatment options (or a combination of these) and will
be valuable in the development of new safer progesta-
tional agents. Moreover, as we now know that it is likely
that only a subset of epithelial cells in the breast possess
the potential to give rise to malignancies, these gene sets
may represent key tools in the identification and isola-
tion of such subpopulations.Through the altruistic tissue donations by healthy
women to the KTB, this unique repository of normal
breast tissue and matched serum, plasma, and DNA is
the largest of its kind in the world. The challenges in
studying cancer initiation and progression in humans
in vivo present a critical imperative for normal human
tissue resources, such as the KTB, to facilitate investiga-
tion into the complete evolution of breast cancer and,
indeed, any type of cancer. That is, in order to determine
what is abnormal, we need to fully define what is
normal.
Abbreviation
KTB: Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer
Center.
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